-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A few days ago, the official website of CDE showed that Chengdu Yuandong Biopharmaceutical|Guangdong Xinghao Pharmaceutical's Palonosetron Hydrochloride Injection has been accepted as imitation 4 types of production, and it will be deemed to have been approved.
Data show that Palonosetron Hydrochloride Injection is a second-generation long-acting 5-HT3 receptor antagonist.
Sales of Palonosetron Injection in the Terminals of Public Medical Institutions in China in Recent Years
Source: Terminal competition landscape of China's public medical institutions
According to data from Minai.
Source: MED2.
There are 15 manufacturers of Palonosetron Hydrochloride Injection including Qilu Pharmaceutical (Hainan), Zhengda Tianqing Pharmaceutical Group, Yangtze River Sichuan Hairong Pharmaceutical, Jiangsu Hengrui Pharmaceutical, among which Qilu Pharmaceutical (Hainan) and Liaoning Haisco The two pharmaceutical companies have been approved for supplementary applications.
Source: CDE official website, Minet database